Updated on 16 May 2015
In 2013, 9 million people fell ill with TB and 1.5 million died from the disease
Singapore: The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.
"When new effective medicines emerge to safely treat serious and widespread diseases, it is vital to ensure that everyone who needs them can obtain them," said WHO director-general, Dr Margaret Chan. "Placing them on the list is a first step in that direction."
Increasingly, governments and institutions around the world are using the WHO list to guide the development of their own essential medicines lists, because they know that every medicine listed has been vetted for efficacy, safety and quality, and that there has been a comparative cost-effectiveness evaluation with other alternatives in the same class of medicines.
The list is updated every two years by an expert committee, made up of recognized specialists from academia, research and the medical and pharmaceutical professions.
This year, the committee underscored the urgent need to take action to promote equitable access and use of several new highly effective medicines, some of which are currently too costly even for high-income countries.
These included new medicines to treat hepatitis C, which affects about 150 million people globally, killing approximately half a million people each year, when chronic infection develops into liver cirrhosis or liver cancer.